Arcus Biosciences (NYSE:RCUS) Price Target Raised to $26.00

Posted by Stanley Muller on Aug 9th, 2026

Arcus Biosciences (NYSE:RCUS – Free Report) had its price objective hoisted by Wells Fargo & Company from $23.00 to $26.00 in a report issued on Thursday,Benzinga reports. They currently have an equal weight rating on the stock.

RCUS has been the topic of several other reports. Truist Financial began coverage on shares of Arcus Biosciences in a research note on Monday, May 18th. They set a “buy” rating and a $35.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Friday, July 17th. Morgan Stanley upped their price objective on Arcus Biosciences from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Monday, May 11th. HC Wainwright upped their price objective on Arcus Biosciences from $32.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Finally, The Goldman Sachs Group increased their price objective on Arcus Biosciences from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.70.

Get Our Latest Stock Report on Arcus Biosciences

Arcus Biosciences Stock Up 1.2%

Shares of NYSE RCUS opened at $28.67 on Thursday. Arcus Biosciences has a 12-month low of $8.88 and a 12-month high of $31.74. The firm’s 50-day simple moving average is $27.40 and its 200 day simple moving average is $24.26. The company has a quick ratio of 4.04, a current ratio of 3.82 and a debt-to-equity ratio of 0.22. The company has a market cap of $3.65 billion, a price-to-earnings ratio of -7.35 and a beta of 0.80.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.17. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The firm had revenue of $41.00 million during the quarter, compared to analysts’ expectations of $21.98 million. The business’s revenue was down 74.4% compared to the same quarter last year. On average, research analysts expect that Arcus Biosciences will post -3.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Arcus Biosciences

In related news, CAO Alexander Azoy sold 2,562 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $25.77, for a total value of $66,022.74. Following the completion of the sale, the chief accounting officer owned 39,581 shares in the company, valued at $1,020,002.37. This represents a 6.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Juan C. Jaen sold 20,067 shares of the company’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $28.62, for a total transaction of $574,317.54. Following the completion of the sale, the president owned 822,240 shares of the company’s stock, valued at approximately $23,532,508.80. This represents a 2.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 110,325 shares of company stock valued at $3,174,319. Corporate insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Arcus Biosciences in the second quarter worth about $506,113,000. Vanguard Group Inc. lifted its holdings in shares of Arcus Biosciences by 20.1% during the 4th quarter. Vanguard Group Inc. now owns 7,962,874 shares of the company’s stock valued at $189,755,000 after purchasing an additional 1,333,421 shares in the last quarter. Suvretta Capital Management LLC lifted its holdings in shares of Arcus Biosciences by 40.7% during the 4th quarter. Suvretta Capital Management LLC now owns 5,188,858 shares of the company’s stock valued at $123,650,000 after purchasing an additional 1,500,000 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Arcus Biosciences by 309.4% in the 4th quarter. Wellington Management Group LLP now owns 5,184,509 shares of the company’s stock valued at $123,547,000 after purchasing an additional 3,918,220 shares during the period. Finally, State Street Corp grew its position in shares of Arcus Biosciences by 34.8% in the 4th quarter. State Street Corp now owns 4,576,969 shares of the company’s stock valued at $109,069,000 after purchasing an additional 1,182,115 shares during the period. 92.89% of the stock is owned by institutional investors and hedge funds.

Arcus Biosciences Company Profile

(Get Free Report)

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.